<DOC>
	<DOCNO>NCT02536196</DOCNO>
	<brief_summary>The Keystone Heart TriGuard™ HDH aortic embolism deflection device intend reduce amount embolic material may enter carotid , subclavian , vertebral artery transcatheter heart valve implantation . The objective study ass safety efficacy TriGuard™ HDH embolic deflection device patient undergoing transcatheter aortic valve implantation ( TAVI ) , comparison active control group patient undergo unprotected TAVI . Subjects indication TAVI meet study eligibility criterion randomize 2:1 one two treatment arm : 1 ) Intervention : Embolic protection device ( TriGuard™ ) transcatheter aortic valve implantation 2 ) Control : Unprotected transcatheter aortic valve implantation .</brief_summary>
	<brief_title>The REFLECT Trial : Cerebral Protection Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Subjects must meet ALL follow criterion : General Inclusion Criteria 1 . The patient male nonpregnant female ≥18 year age 2 . The patient meet indication transcatheter aortic valve implantation ( TAVI ) 3 . The patient willing comply protocolspecified followup evaluation 4 . The patient , legally authorize representative , informed nature study , agree provision provide write informed consent , approve appropriate Institutional Review Board ( IRB ) Ethics Committee ( EC ) . Potential Subjects exclude ANY follow criterion apply : General Exclusion Criteria 1 . Patients undergoing transcatheter aortic valve implantation ( TAVI ) via transaxillary , transsubclavian , transaortic route 2 . Patients undergoing transcatheter aortic valve implantation ( TAVI ) via transapical approach due friable mobile atherosclerotic plaque aortic arch 3 . Patients previously implant prosthetic aortic valve ( i.e. , plan valveinvalve transcatheter aortic valve implantation ( TAVI ) ) 4 . Pregnant nursing subject plan pregnancy period 1 year follow index procedure . Female subject childbearing potential must negative pregnancy test do within 14 day prior index procedure per site standard test 5 . Patients know diagnosis acute myocardial infarction ( AMI ) within 72 hour precede index procedure ( accord definition ) AMI &gt; 72 hour precede index procedure , Creatine Kinase ( CK ) CKMB return within normal limit time procedure , patient currently experience clinical symptom consistent newonset AMI , nitrateunresponsive prolong chest pain 6 . Patients history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate , patient refuse transfusion , patient active peptic ulcer history upper gastrointestinal ( GI ) bleeding within prior 3 month 7 . Patients know mental physical illness know history substance abuse may cause noncompliance protocol , confound data interpretation , associate life expectancy le one year 8 . Patients severe allergy know hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel , nitinol , stainless steel alloy , and/or contrast sensitivity adequately premedicated 9 . Patients history stroke transient ischemic attack ( TIA ) within prior 6 month 10 . Patients renal failure ( estimate Glomerular Filtration Rate [ eGFR ] &lt; 30 mL/min , calculate serum creatinine CockcroftGault formula ) 11 . Patients hepatic failure ( ChildPugh class C ) 12 . Patients hypercoagulable state correct additional periprocedural heparin 13 . Patients present cardiogenic shock time index procedure 14 . Patients severe peripheral arterial , abdominal aortic , thoracic aortic disease precludes delivery sheath vascular access 15 . Patients aortic arch , innominate artery ostium , proximal innominate artery heavily calcify , severely atheromatous , severely tortuous 16 . Patients innominate artery ostium diameter &lt; 10 mm &gt; 25 mm 17 . Patients transverse aortic diameter &gt; 43 18 . Patients anatomic irregularity innominate artery could prevent position TriGuard upper stabilizer compromise stability device 19 . Patients condition would prevent adherence TriGuard HDH Instructions Use 20 . Patients contraindication cerebral MRI 21 . Patients plan treatment investigational device procedure study period 22 . Patients plan undergo cardiac surgical interventional procedure ( e.g. , concurrent coronary revascularization ) TAVI procedure within 10 day prior TAVI procedure . NOTE : Diagnostic cardiac catheterization permit within 10 day prior TAVI procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cerebral protection , aortic stenosis , transcatheter aortic valve implantation , TAVI , TriGuard , Keystone Heart</keyword>
</DOC>